WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Critical Alert Systems
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Proactive Investors | April 08, 2020
The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in th...
Cell and Gene Therapy, Industrial Impact
Ligand Pharmaceuticals | February 21, 2023
In a recent announcement by biopharmaceutical firm, Ligand Pharmaceuticals, the U.S. Food and Drug Administration (FDA) has given accelerated approval for FILSPARITM (sparsentan). This will be helpful in treating adults with primary IgAN condition who are at risk of rapid disease progression, typically defined as a urine protein-to-creatinine ratio (UPCR) of less than 1.5 g/g. FILSPARI, a once-daily oral medicine, is the first and only non-immunosuppressive therapy authorized fo...
Industrial Impact, Medical
businesswire | April 20, 2023
Asahi Kasei Bioprocess America, a subsidiary of diversified Japanese multinational company Asahi Kasei, and GeminiBio have entered into a strategic partnership to advance the application of inline buffer formulation (IBF) in the biopharmaceutical industry. Asahi Kasei Bioprocess, with decades of expertise in IBF and the developers of the award-winning MOTIV™ system, and GeminiBio, with industry leading bioprocess liquid manufacturing capabilities, are combining two high-efficiency so...
Rocket Pharmaceuticals, Inc | February 09, 2023
On February 7, 2023, Rocket Pharmaceuticals Inc., a renowned late-stage biotech firm advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet needs, announced that FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501, the company's investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease, a life-threatening genetic cardiac disease with no disease-altering therapies available. RMAT s...
Whitepaper
Industrial Impact
Research, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE